

## Esculentic acid Datasheet

4<sup>th</sup> Edition (Revised in July, 2016)

### [ Product Information ]

**Name:** Esculentic acid

**Catalog No.:** CFN99059

**Cas No.:** 103974-74-9


**Purity:** > 95%

**M.F:** C<sub>30</sub>H<sub>48</sub>O<sub>5</sub>

**M.W:** 488.70

**Physical Description:** Powder

**Synonyms:** 2a,3a,23-Trihydroxyurs-12-en-28-oic acid.



### [ Intended Use ]

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Others.

### [ Source ]

The roots of *Phytolacca acinosa* Roxb.

### [ Biological Activity or Inhibitors ]

Esculentic acid (EA), a pentacyclic triterpenoids compound extracted from the Chinese

herb *Phytolacca esculenta*, has long been used in traditional Chinese medicine for the treatment of rheumatoid arthritis, edema, hepatitis and bronchitis disease; EA possesses potent anti-inflammatory activity both in vivo and in vitro, while the anti-inflammation action in vitro may be attributed to the inhibition of the level of TNF- $\alpha$  and IL-6 pro-inflammatory cytokines and PGE2 inflammatory mediator in macrophages, meanwhile, the production of PGE2 is possibly associated with COX-2 protein expression which is similar to that of NSAIDS.<sup>[1]</sup>

Esculentic acid has protective effects against LPS-induced endotoxic shock, which may be mediated, at least in part, by regulation the release of inflammatory cytokines and mediators, and protein expression of COX-2 in mice.<sup>[2]</sup>

Esculentic acid exhibits anti-complement activity with IC<sub>50</sub> values of 56 microM, it seems to play an important role in inhibiting the hemolytic activity of human serum against erythrocytes. <sup>[3]</sup>

## **[ Solvent ]**

Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.

## **[ HPLC Method ]**

Not data available.

## **[ Storage ]**

2-8°C, Protected from air and light, refrigerate or freeze.

## **[ References ]**

[1] Niu X, Mu Q, Li W, *et al. Eur. J. Pharmacol.*, 2014, 740:532-8.

[2] Niu X, Mu Q, Li W, *et al. Int. Immunopharmacol.*, 2014, 23(1):229-35.

[3] Thuong P T, Min B S, Jin W, *et al. Biol. Pharm. Bull.*, 2006, 29(4):830-3.

## **[ Contact ]**

**Address:**

S5-3 Building, No. 111, Dongfeng Rd.,  
Wuhan Economic and Technological Development Zone,  
Wuhan, Hubei 430056,  
China

**Email:** [info@chemfaces.com](mailto:info@chemfaces.com)

**Tel:** +86-27-84237783

**Fax:** +86-27-84254680

**Web:** [www.chemfaces.com](http://www.chemfaces.com)

**Tech Support:** [service@chemfaces.com](mailto:service@chemfaces.com)